Isolation of humonal monoclonal antibody cross-reactively neutralizing against shiga toxin type 1 and 2 and treating a patient suffering HUS

2014 Fiscal Year Final Research Report

• Project/Area Number: 24590539
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Bacteriology (including Mycology)
• Research Institution: Fujita Health University
• Principal Investigator: TSUJI Takao 藤田保健衛生大学, 医学部, 教授 (60171998)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 腸管出血性大腸菌 / 致死毒素（Stx1と2） / 経鼻投与ワクチン / ヒトモノクローナル抗体 / HUS治療薬

Outline of Final Research Achievements

Enterohemorrhagic Escherichia coli (EHEC) produces Stx1 and Stx2 causing severe diseases like hemolytic uremic syndrome (HUS). As there is no vaccine or no curative for these diseases caused by both toxins, we have been trying to isolate monoclonal antibody or polyclonal antibodies cross-reactively neutralizing both toxins. We already reported that nasal subunit-vaccine such as Stx2B-His with a mutant heat-labile enterotoxin induced polyclonal antibodies cross-reactively neutralizing both toxins （Vaccine,24:3591,2006、26:469,2008、26:2092.2008）.Then, in this project, we try to isolate a monoclonal antibody, which will neutralize both toxins cross-reactively and use for the treatment of severe diseases like HUS caused by both toxins.

Free Research Field

細菌学